PMID- 8081556
OWN - NLM
STAT- MEDLINE
DCOM- 19941013
LR  - 20231105
IS  - 1067-5582 (Print)
IS  - 1067-5582 (Linking)
VI  - 16
IP  - 1
DP  - 1994 Jul
TI  - Locus-specific analysis of human leukocyte antigen class I expression in melanoma 
      cell lines.
PG  - 13-23
AB  - Surface expression of human leukocyte antigen (HLA) class I antigens on melanoma 
      lines was evaluated by locus-specific monoclonal antibodies (mAbs) with three 
      different techniques: Fluorescence-activated cell sorting (FACS), 
      immunohistochemistry with cytospin preparation (ICP), and complement-mediated 
      cytotoxicity (CMC). Eleven HLA class I-expressing cell lines developed from 
      metastases were used. Specific expression of HLA loci was examined under routine 
      culture conditions and after 48-h incubation in interferon-gamma (IFN-gamma; 500 
      U/ml). Loss of allelic expression was seen in one line (586-MEL): Products of 
      genes coding for HLA-A29 and -B44, in strong linkage disequilibrium, were not 
      detectable. HLA-A antigens were consistently detected by all methodologies and 
      minimally affected by pretreatment with IFN-gamma. HLA-B antigens were detectable 
      in 8 of 11 lines by ICP and 3 of 11 lines by CMC. By FACS the supratypic 
      specificity HLA-Bw6 was expressed at low levels in most lines (mean fluorescence 
      47.2 +/- 13.4 and rose to 259.8 +/- 45.9 after incubation with IFN-gamma; p < 
      0.001). HLA-Cw antigen detection by CMC correlated with HLA-B (p < 0.01), 
      suggesting that down-regulation and sensitivity to IFN-gamma are shared by the 
      two loci. This low expression of the HLA-B antigens may play a role in the 
      evasion of the host immune response and its up-regulation may be useful in 
      allowing tumor antigen recognition.
FAU - Marincola, F M
AU  - Marincola FM
AD  - Surgery Branch, Clinical Oncology Program, Division of Cancer Treatment, National 
      Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
FAU - Shamamian, P
AU  - Shamamian P
FAU - Simonis, T B
AU  - Simonis TB
FAU - Abati, A
AU  - Abati A
FAU - Hackett, J
AU  - Hackett J
FAU - O'Dea, T
AU  - O'Dea T
FAU - Fetsch, P
AU  - Fetsch P
FAU - Yannelli, J
AU  - Yannelli J
FAU - Restifo, N P
AU  - Restifo NP
FAU - Mule, J J
AU  - Mule JJ
AU  - et al.
LA  - eng
GR  - NIH0010139353/ImNIH/Intramural NIH HHS/United States
GR  - Z01 BC010763-01/ImNIH/Intramural NIH HHS/United States
GR  - Z99 TW999999/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - J Immunother Emphasis Tumor Immunol
JT  - Journal of immunotherapy with emphasis on tumor immunology : official journal of 
      the Society for Biological Therapy
JID - 9418950
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Cytotoxicity Tests, Immunologic
MH  - Flow Cytometry
MH  - HLA-A Antigens/*analysis/blood
MH  - HLA-B Antigens/*analysis/blood
MH  - Humans
MH  - Immunohistochemistry
MH  - Interferon-gamma/pharmacology
MH  - Lymphocytes/immunology/metabolism
MH  - Melanoma/*immunology/metabolism
MH  - Neoplasm Metastasis
MH  - Tumor Cells, Cultured
PMC - PMC2561308
MID - NIHMS65807
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
PMCR- 2008/10/06
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
PHST- 2008/10/06 00:00 [pmc-release]
AID - 10.1097/00002371-199407000-00002 [doi]
PST - ppublish
SO  - J Immunother Emphasis Tumor Immunol. 1994 Jul;16(1):13-23. doi: 
      10.1097/00002371-199407000-00002.